文献速递糖尿病

SGLT2抑制所致内源性葡萄糖生成增加不受肾去神经支配影响,且与尿糖排泄增加密切相关

Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion.
PubMed 文献 · Diabetes Care · 2020-03-06

研究纳入14例肾移植受者(6例2型糖尿病、8例无糖尿病),在达格列净10 mg或安慰剂后以[3-3H]葡萄糖输注测定内源性葡萄糖生成(EGP)。肾去神经支配未能阻断达格列净对EGP的刺激,达格列净所致EGP升高与尿糖排泄增加强相关(r=0.824;P<0.001),削弱了空腹血糖下降。

要点

  • 肾移植受者中,肾去神经支配未阻断达格列净对EGP的刺激
  • 达格列净后EGP升高与尿糖排泄增加强相关(r=0.824;P<0.001)
  • EGP升高削弱了达格列净引起的空腹血糖下降

核心结论

  • 在肾移植受者中,肾去神经支配未能阻断达格列净介导的EGP刺激,无论2型糖尿病还是无糖尿病者;达格列净所致EGP升高与尿糖排泄增加强相关,削弱空腹血糖下降。

研究设计与样本

  • 14例肾移植受者(6例2型糖尿病[A1C 7.2±0.1%],8例无糖尿病[A1C 5.6±0.1%))接受达格列净10 mg或安慰剂,以[3-3H]葡萄糖输注测定EGP,并测血浆葡萄糖、胰岛素、C肽、胰高血糖素及滴定葡萄糖比活度。

主要发现

  • 2型糖尿病安慰剂组空腹血糖143±14降至124±10 mg/dL(P=0.02),空腹胰岛素12±2降至10±1.1 μU/mL(P<0.05),胰高血糖素不变,EGP下降。
  • 2型糖尿病达格列净组空腹血糖143±15降至112±9 mg/dL(P=0.01),空腹胰岛素14±3降至11±2 μU/mL(P=0.02),胰高血糖素升高(均P<0.05 vs 安慰剂)。
  • 2型糖尿病达格列净组EGP较基线无变化(2.21±0.19 vs 1.96±0.14 mg/kg/min,P<0.001 vs 安慰剂)。
  • 无糖尿病达格列净组空腹血糖和空腹胰岛素下降、胰高血糖素不变,EGP较基线无变化(1.85±0.10降至1.78±0.10 mg/kg/min),而安慰剂组EGP显著下降。
  • 所有患者达格列净与安慰剂相比EGP增加与尿糖排泄差值呈强相关(r=0.824;P<0.001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sodium-glucose cotransporter 2 (SGLT2) inhibition causes an increase in endogenous glucose production (EGP). However, the mechanisms are unclear. We studied the effect of SGLT2 inhibitors on EGP in subjects with type 2 diabetes (T2D) and without diabetes (non-DM) in kidney transplant recipients with renal denervation. RESEARCH DESIGN AND METHODS: Fourteen subjects who received a renal transplant (six with T2D [A1C 7.2 ± 0.1%] and eight non-DM [A1C 5.6 ± 0.1%) underwent measurement of EGP with [3-3H]glucose infusion following dapagliflozin (DAPA) 10 mg or placebo. Plasma glucose, insulin, C-peptide, glucagon, and titrated glucose-specific activity were measured. RESULTS: Following placebo in T2D, fasting plasma glucose (FPG) (143 ± 14 to 124 ± 10 mg/dL; P = 0.02) and fasting plasma insulin (12 ± 2 to 10 ± 1.1 μU/mL; P < 0.05) decreased; plasma glucagon was unchanged, and EGP declined. After DAPA in T2D, FPG (143 ± 15 to 112 ± 9 mg/dL; P = 0.01) and fasting plasma insulin (14 ± 3 to 11 ± 2 μU/mL; P = 0.02) decreased, and plasma glucagon increased (all P < 0.05 vs. placebo). EGP was unchanged from baseline (2.21 ± 0.19 vs. 1.96 ± 0.14 mg/kg/min) in T2D (P < 0.001 vs. placebo). In non-DM following DAPA, FPG and fasting plasma insulin decreased, and plasma glucagon was unchanged. EGP was unchanged from baseline (1.85 ± 0.10 to 1.78 ± 0.10 mg/kg/min) after DAPA, whereas EGP declined significantly with placebo. When the increase in EGP production following DAPA versus placebo was plotted against the difference in urinary glucose excretion (UGE) for all patients, a strong correlation (r = 0.824; P < 0.001) was observed. CONCLUSIONS: Renal denervation in patients who received a kidney transplant failed to block the DAPA-mediated stimulation of EGP in both individuals with T2D and non-DM subjects. The DAPA-stimulated rise in EGP is strongly related to the increase in UGE, blunting the decline in FPG.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Solis-Herrera C, Daniele G, Alatrach M, et al. Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion. Diabetes Care. 2020. PMID: 32144165. doi:10.2337/dc19-2177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。